Peptide drugs are a class of drugs with extremely rapid market growth. The rapid development of peptide drugs is mainly reflected in the production technology of peptide drugs and the large-scale preparation technology of peptide APIs.
In terms of peptide APIs, some domestic manufacturers have reached a high level. Taking advantage of self-produced APIs to develop downstream peptide generic drugs has become the general trend of the development of domestic peptide pharmaceutical companies. A new wave of development opportunities is ushered in domestic peptide drug generic drugs.
Following this, the R&D and production of generic drugs has driven the growth of upstream APIs, and has also driven the rapid growth of upstream amino acid, amino acid protective agent and other intermediate products. Many domestic related product companies have also benefited from this. As a R&D and production enterprise with di-tert-butyl dicarbonate (Di-Boc, CAS No.24424-99-5) as its core product, in order to ensure that under the situation of rapid growth in market demand, Various manufacturing companies provide high-quality products, and in 2020, they will quickly develop into the most professional Di-Boc manufacturer in China.
